Form 4: Omnicell Director Edward Bousa Receives Equity Grant as Board Compensation

Omnicell, Inc. Director Edward Peter Bousa was granted 6,486 restricted shares of common stock as compensation for his board services, increasing his total beneficial ownership to 17,986 shares.

Summary

• Edward Peter Bousa, a Director of Omnicell, Inc. (OMCL), acquired 6,486 shares of common stock on June 1, 2025.
• The acquisition was a grant of restricted shares under the Issuer's equity incentive plan, specifically for services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan.
• The shares were granted at a price of $0, indicating they were compensation rather than a purchase.
• Following this transaction, Edward Peter Bousa beneficially owns a total of 17,986 shares of Omnicell common stock.
• The granted shares are scheduled to vest in full on the one-year anniversary of the grant date, which is June 1, 2026.

Sentiment

Score: 7

Explanation: The document reports a standard and expected equity grant to a director, which is a positive for aligning interests and is a routine part of corporate compensation, indicating stability rather than any negative surprises.

Positives

• The grant of restricted shares to a director aligns the interests of the board member with those of the shareholders, promoting long-term value creation.
• This transaction represents a standard and expected form of non-cash compensation for board services, reflecting good corporate governance practices.

Future Outlook

The granted restricted shares are scheduled to vest in full on June 1, 2026, which is the one-year anniversary of the grant date.

Management Comments

• "Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the one-year anniversary of the grant date."

Industry Context

The grant of equity compensation to non-employee directors is a common practice across publicly traded companies in various industries, including healthcare technology, to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The practice of compensating board members with equity, such as restricted stock units, is a widely adopted standard in corporate governance across global markets, including companies like Medtronic (MDT) or Baxter International (BAX) in the healthcare sector, which often use similar equity-based compensation plans for their directors.
• The vesting schedule of one year is also a common structure for director equity grants, ensuring continued service and commitment.

Corporate Governance

Related Party Transactions

• The grant of restricted shares to Edward Peter Bousa, a Director of Omnicell, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on employees is indicated by this specific filing, though it reflects the company's overall compensation philosophy.

Next Steps

• Vesting of the 6,486 restricted shares on June 1, 2026.

Key Dates

Recommendation

Keywords

Omnicell, OMCL, Form 4, Insider Transaction, Equity Grant, Restricted Stock, Director Compensation, Beneficial Ownership, Corporate Governance